Glaukos has announced its iDose TR travoprost implant has demonstrated intraocular pressure (IOP) reduction and favourable safety profile over 36 months in a phase 2b study.
Of the study’s 154 open-angle glaucoma (OAG) or ocular hypertension patients, 70% and 68% of subjects in the fast- and slow-release iDose TR arms, respectively, were well-controlled with the same or fewer IOP-lowering topical medications at 36 months versus screening; versus 46% of subjects in the topical 0.5% timolol solution BID control arm. No clinically significant corneal endothelial cell loss or serious adverse events of periorbital fat atrophy and conjunctival hyperaemia were reported.
“These latest phase 2 results further underscore the potential of iDose TR to safely provide multiple years of sustained dropless therapy and help tackle the significant problem of patient non-adherence to and chronic side effects associated with topical glaucoma medication regimens,” said Thomas Burns, Glaukos president and CEO.
